ESC 365 - From genes to trials in China: Lp(a) and ANGPTL3/4/8 as emerging atherosclerotic cardiovascular disease targets beyond LDL-C and inflammation?

ESC2025 Premium Access

From genes to trials in China: Lp(a) and ANGPTL3/4/8 as emerging atherosclerotic cardiovascular disease targets beyond LDL-C and inflammation?

Session: New insights on preventing atherosclerosis: perspectives from China

Topic: Atherosclerosis, Cerebrovascular Diseases, Aneurysm, Restenosis

Speaker: Professor Y. Tang (Beijing, CN)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Professor Yida Tang

Peking University Third Hospital, Beijing (China)

1 presentation

0 follower

2 more presentations in this session

Statins aggravate insulin resistance through reduced blood glucagon-like peptide-1 levels in a microbiota-dependent manner in Chinese cohorts/patients

Speaker: Doctor J. She (Xi'an, CN)

New insights on preventing atherosclerosis: perspectives from China - discussion

Access the full session

New insights on preventing atherosclerosis: perspectives from China

Speakers: Professor Y. Tang, Doctor J. She

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources